A share price of Day One Biopharmaceuticals Inc [DAWN] is currently trading at $10.59, down -6.53%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The DAWN shares have gain 22.57% over the last week, with a monthly amount glided 25.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Piper Sandler started tracking the stock with Overweight rating on August 19, 2025, and set its price target to $25. On October 09, 2024, Needham reiterated its Buy rating and revised its price target to $33 on the stock. BofA Securities upgraded its rating to a Buy and increased its price target to $24 on August 01, 2024. Needham reiterated its recommendation of a Buy and raised its price target to $33 on April 24, 2024. BofA Securities downgraded its rating to Underperform for this stock on April 25, 2023, and downed its price target to $9. In a note dated February 08, 2023, CapitalOne initiated an Overweight rating and provided a target price of $40 on this stock.
Day One Biopharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $5.64 and $13.53. Currently, Wall Street analysts expect the stock to reach $26 within the next 12 months. Day One Biopharmaceuticals Inc [NASDAQ: DAWN] shares were valued at $10.59 at the most recent close of the market. An investor can expect a potential return of 145.51% based on the average DAWN price forecast.
Analyzing the DAWN fundamentals
Trailing Twelve Months sales for Day One Biopharmaceuticals Inc [NASDAQ:DAWN] were 133.67M which represents -57.56% decline. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.24%, Pretax Profit Margin comes in at -1.09%, and Net Profit Margin reading is -1.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.32 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Day One Biopharmaceuticals Inc [NASDAQ:DAWN] is 8.68. In addition, the Quick Ratio stands at 8.55 and the Cash Ratio stands at 0.77. Considering the valuation of this stock, the price to sales ratio is 8.37, the price to book ratio is 2.41.
Transactions by insiders
Recent insider trading involved Dubow Adam, Gen Counsel & Secretary, that happened on Nov 17 ’25 when 4319.0 shares were sold. COO and CFO, York Charles N II completed a deal on Nov 17 ’25 to sell 4062.0 shares. Meanwhile, Chief Commercial Officer Merendino Lauren sold 3726.0 shares on Nov 17 ’25.
